Compare BOW & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOW | TBPH |
|---|---|---|
| Founded | 2020 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 913.3M | 1.0B |
| IPO Year | 2024 | 2013 |
| Metric | BOW | TBPH |
|---|---|---|
| Price | $22.37 | $14.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $34.29 | $18.50 |
| AVG Volume (30 Days) | 218.4K | ★ 830.5K |
| Earning Date | 05-05-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.26 | ★ 279.13 |
| EPS | 1.59 | ★ 2.06 |
| Revenue | ★ $551,589,000.00 | $15,386,000.00 |
| Revenue This Year | $21.14 | $9.51 |
| Revenue Next Year | $19.15 | N/A |
| P/E Ratio | ★ $13.63 | $16.23 |
| Revenue Growth | ★ 29.58 | N/A |
| 52 Week Low | $21.21 | $7.90 |
| 52 Week High | $42.29 | $21.03 |
| Indicator | BOW | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 40.21 | 40.20 |
| Support Level | $22.15 | $13.41 |
| Resistance Level | $26.17 | $15.22 |
| Average True Range (ATR) | 0.82 | 0.44 |
| MACD | -0.13 | 0.14 |
| Stochastic Oscillator | 29.94 | 89.80 |
Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity and hospitality segments and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).